Gilead Sciences Inc. closed 13.61% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Argenx ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

Gilead Sciences, Inc. (GILD), based in Foster City, California, is a leading biopharmaceutical company focused on developing and commercializing groundbreaking therapies for diseases like HIV ...

Originally published by Gilead Sciences. View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal. MiroBio was formed in 2019 to ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.